Other Insights from FSI

This paper lays out FSI's funnel for sizing the reachable population behind a first-in-class asset, the diagnostic and payer readiness gaps that delay adoption, and five questions to answer before a Phase 3 commitment.

Why capital is flowing to neuroscience companies that can show commercial differentiation on top of positive clinical data.

Agentic AI for Pharma Commercialization Go-to-Market Strategy
Medical Device Competitive Positioning & Board Advisory
AI-Enabled Cardiac Device Market Entry Strategy
Emerging Cardiovascular Device Commercial & Fundraising Assessment
Academic Medical Center Digital Health Investment Strategy
Chronic Hypoparathyroidism Patient Journey & Launch Strategy
Prostate Cancer Diagnostics US Partnering & Commercialization Strategy